Alphaton Capital已与Immunova达成具有法律约束力的看涨期权协议，正式启动其传统生物技术资产Iox Therapeutics的剥离程序。这项交易标志着Alphaton Capital对其投资组合进行战略性优化的关键一步。
通过执行该期权协议，Alphaton Capital将把其在Iox Therapeutics的全部权益转让给Immunova。Iox Therapeutics作为一项历史资产，此次出售符合Alphaton Capital专注于核心投资战略的长期规划。
Alphaton Capital已与Immunova达成具有法律约束力的看涨期权协议，正式启动其传统生物技术资产Iox Therapeutics的剥离程序。这项交易标志着Alphaton Capital对其投资组合进行战略性优化的关键一步。
通过执行该期权协议，Alphaton Capital将把其在Iox Therapeutics的全部权益转让给Immunova。Iox Therapeutics作为一项历史资产，此次出售符合Alphaton Capital专注于核心投资战略的长期规划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.